A majority of surveyed US gastroenterologists are highly familiar with Entyvio (vedolizumab), with 62% reporting they have prescribed Entyvio, produced by Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502), to at least one of their ulcerative colitis (UC) or Crohn’s disease (CD) patients.
According to market research group Decision Resources, many surveyed and interviewed physicians cite Entyvio's new mechanism of action and its efficacy as a perceived advantage as lack or loss of response in patients using anti-TNF agents is a substantial concern. Although clinical data suggest weaker efficacy in CD than UC, and that the theoretical risk of PML is still a concern for many surveyed physicians, a majority of gastroenterologists indicate a high level of willingness to prescribe Entyvio for both UC and CD.
Other key findings from the LaunchTrends report titled "Entyvio Wave 3 (US)"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze